Stocksigma LogoStocksigma Logo

Rossari Biotech Posts 19% Revenue Growth in Q2FY27 Alongside Saudi Expansion

Rossari Biotech reported Q2FY27 consolidated revenue of Rs. 697.6 crores, up 19.0% YoY, while EBITDA rose 20.9% YoY to Rs

Rossari Biotech Posts 19% Revenue Growth in Q2FY27 Alongside Saudi Expansion

Rossari Biotech Ltd 路 Investor Presentation 路 19 Oct 2026, 6:07 am

Rossari Biotech Posts 19% Revenue Growth in Q2FY27 Alongside Saudi Expansion Rossari Biotech reported Q2FY27 consolidated revenue of Rs. 697.6 crores, up 19.0% YoY, while EBITDA rose 20.9% YoY to Rs. 87.0 crores with margins at 12.5%. PAT grew 5.4% YoY to Rs. 38.9 crores, moderated by higher project depreciation. Exports surged 33.8% YoY to Rs. 216.4 crores. By segment, HPPC grew 18%, TSC 26%, and AHN 11% YoY. H1FY27 net debt declined to Rs. 221 crores from Rs. 281 crores in Mar'26, and working capital reduced to 86 days. The board approved leasing land for a greenfield facility in Saudi Arabia.

Original exchange filing (PDF)

More announcements from Rossari Biotech Ltd

All Rossari Biotech Ltd announcements